CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance

Christopher T. Lucido, Paola D. Vermeer, Bryant G. Wieking, Daniel W. Vermeer, John H. Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Standard-of-care cisplatin and radiation therapy (CRT) provides significant tumor control of human papillomavirus (HPV)-mediated head and neck squamous cell carcinomas (HNSCCs); this effectiveness depends on CRT-mediated activation of the patient’s own immune system. However, despite good survival, patients suffer significant morbidity necessitating on-going studies to define novel therapies that alleviate this burden. Given the role of the immune system in tumor clearance, immune modulation may further potentiate the CRT-activated response while potentially decreasing morbidity. CD137, an inducible cell surface receptor found on activated T cells, is involved in differentiation and survival signaling in T cells upon binding of its natural partner (CD137L). A number of studies have shown the effectiveness of targeting this immune-stimulatory pathway in regards to tumor clearance. Here, we test its role in HPV+ HNSCC tumor clearance using a previously characterized mouse model. We show that amplification of this stimulatory pathway synergizes with CRT for enhanced tumor clearance. Interestingly, tumor clearance is further potentiated by local tumor cell expression of CD137L.

Original languageEnglish (US)
Pages (from-to)841-853
Number of pages13
JournalVaccines
Volume2
Issue number4
DOIs
StatePublished - Dec 10 2014

Fingerprint

Cisplatin
Radiotherapy
Neoplasms
Immune System
Morbidity
T-Lymphocytes
Survival
Cell Surface Receptors
Standard of Care
Carcinoma, squamous cell of head and neck
Therapeutics

Keywords

  • CD137
  • HPV
  • Immune
  • Mouse
  • Squamous

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance. / Lucido, Christopher T.; Vermeer, Paola D.; Wieking, Bryant G.; Vermeer, Daniel W.; Lee, John H.

In: Vaccines, Vol. 2, No. 4, 10.12.2014, p. 841-853.

Research output: Contribution to journalArticle

Lucido, Christopher T. ; Vermeer, Paola D. ; Wieking, Bryant G. ; Vermeer, Daniel W. ; Lee, John H. / CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance. In: Vaccines. 2014 ; Vol. 2, No. 4. pp. 841-853.
@article{3ff93753bed448edb694d91d82f82916,
title = "CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance",
abstract = "Standard-of-care cisplatin and radiation therapy (CRT) provides significant tumor control of human papillomavirus (HPV)-mediated head and neck squamous cell carcinomas (HNSCCs); this effectiveness depends on CRT-mediated activation of the patient’s own immune system. However, despite good survival, patients suffer significant morbidity necessitating on-going studies to define novel therapies that alleviate this burden. Given the role of the immune system in tumor clearance, immune modulation may further potentiate the CRT-activated response while potentially decreasing morbidity. CD137, an inducible cell surface receptor found on activated T cells, is involved in differentiation and survival signaling in T cells upon binding of its natural partner (CD137L). A number of studies have shown the effectiveness of targeting this immune-stimulatory pathway in regards to tumor clearance. Here, we test its role in HPV+ HNSCC tumor clearance using a previously characterized mouse model. We show that amplification of this stimulatory pathway synergizes with CRT for enhanced tumor clearance. Interestingly, tumor clearance is further potentiated by local tumor cell expression of CD137L.",
keywords = "CD137, HPV, Immune, Mouse, Squamous",
author = "Lucido, {Christopher T.} and Vermeer, {Paola D.} and Wieking, {Bryant G.} and Vermeer, {Daniel W.} and Lee, {John H.}",
year = "2014",
month = "12",
day = "10",
doi = "10.3390/vaccines2040841",
language = "English (US)",
volume = "2",
pages = "841--853",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance

AU - Lucido, Christopher T.

AU - Vermeer, Paola D.

AU - Wieking, Bryant G.

AU - Vermeer, Daniel W.

AU - Lee, John H.

PY - 2014/12/10

Y1 - 2014/12/10

N2 - Standard-of-care cisplatin and radiation therapy (CRT) provides significant tumor control of human papillomavirus (HPV)-mediated head and neck squamous cell carcinomas (HNSCCs); this effectiveness depends on CRT-mediated activation of the patient’s own immune system. However, despite good survival, patients suffer significant morbidity necessitating on-going studies to define novel therapies that alleviate this burden. Given the role of the immune system in tumor clearance, immune modulation may further potentiate the CRT-activated response while potentially decreasing morbidity. CD137, an inducible cell surface receptor found on activated T cells, is involved in differentiation and survival signaling in T cells upon binding of its natural partner (CD137L). A number of studies have shown the effectiveness of targeting this immune-stimulatory pathway in regards to tumor clearance. Here, we test its role in HPV+ HNSCC tumor clearance using a previously characterized mouse model. We show that amplification of this stimulatory pathway synergizes with CRT for enhanced tumor clearance. Interestingly, tumor clearance is further potentiated by local tumor cell expression of CD137L.

AB - Standard-of-care cisplatin and radiation therapy (CRT) provides significant tumor control of human papillomavirus (HPV)-mediated head and neck squamous cell carcinomas (HNSCCs); this effectiveness depends on CRT-mediated activation of the patient’s own immune system. However, despite good survival, patients suffer significant morbidity necessitating on-going studies to define novel therapies that alleviate this burden. Given the role of the immune system in tumor clearance, immune modulation may further potentiate the CRT-activated response while potentially decreasing morbidity. CD137, an inducible cell surface receptor found on activated T cells, is involved in differentiation and survival signaling in T cells upon binding of its natural partner (CD137L). A number of studies have shown the effectiveness of targeting this immune-stimulatory pathway in regards to tumor clearance. Here, we test its role in HPV+ HNSCC tumor clearance using a previously characterized mouse model. We show that amplification of this stimulatory pathway synergizes with CRT for enhanced tumor clearance. Interestingly, tumor clearance is further potentiated by local tumor cell expression of CD137L.

KW - CD137

KW - HPV

KW - Immune

KW - Mouse

KW - Squamous

UR - http://www.scopus.com/inward/record.url?scp=85016854953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016854953&partnerID=8YFLogxK

U2 - 10.3390/vaccines2040841

DO - 10.3390/vaccines2040841

M3 - Article

C2 - 25984365

AN - SCOPUS:85016854953

VL - 2

SP - 841

EP - 853

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 4

ER -